Page 2 - Eric Benevich News Today

Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,150 shares of the company’s stock, valued at approximately $415,000. A number of other hedge funds also recently modified their […]

Yousif Capital Management LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,808 shares of the company’s stock after selling 370 shares during the quarter. Yousif Capital Management LLC’s […]

New York State Common Retirement Fund lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% during the 4th quarter, Holdings Channel reports. The firm owned 214,396 shares of the company’s stock after selling 29,456 shares during the quarter. New York State Common Retirement Fund’s holdings in Neurocrine Biosciences were worth $28,249,000 […]

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average […]

Wedbush reissued their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $147.00 target price on the stock. A number of other analysts also recently weighed in on NBIX. JPMorgan Chase & Co. increased their price target on shares […]

On February 13, 2024, Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 1,098 shares of the company.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript February 7, 2024 Neurocrine Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all […]

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good day, everyone. And welcome to the Neurocrine Biosciences Reports third quarter results. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call […]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript August 1, 2023 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $0.77. Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today’s program over to Todd […]